As of today (2026-06-28), the Forward Annual Dividend Yield of ACADIA Pharmaceuticals is 0.00%.
As of today (2026-06-28), the Trailing Annual Dividend Yield of ACADIA Pharmaceuticals is 0.00%.
MEX:ACAD's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.57 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
ACADIA Pharmaceuticals Forward Dividend Yield % Related Terms
MEX:ACAD vs EWTX, CRNX, VKTX: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, ACADIA Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACADIA Pharmaceuticals Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where ACADIA Pharmaceuticals's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
ACADIA Pharmaceuticals (MEX:ACAD) has a Forward Dividend Yield % of 0.00% as of Jun. 28, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on ACADIA Pharmaceuticals and its competitors. According to the industry distribution chart, ACADIA Pharmaceuticals ranks #999999 out of 145 companies in the Biotechnology industry.
Is ACADIA Pharmaceuticals' Forward Dividend Yield % too high?
ACADIA Pharmaceuticals' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, ACADIA Pharmaceuticals ranks #999999 out of 145 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ACADIA Pharmaceuticals has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Forward Dividend Yield % compare to EWTX and CRNX?
According to the Biotechnology industry distribution chart, ACADIA Pharmaceuticals ranks #999999 out of 145 companies for Forward Dividend Yield %. This places ACADIA Pharmaceuticals in the lower half of its industry. The industry median Forward Dividend Yield % is 1.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.57, based on 145 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on ACADIA Pharmaceuticals and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACADIA Pharmaceuticals's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Fairly Valued. The stock's GF Value™ is MXN357.71, compared to a current price of MXN362.00 — trading 1.2% above its estimated fair value. The current Forward Dividend Yield % is 0.00%. ACADIA Pharmaceuticals' overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current Forward Dividend Yield % is 0.00% as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN362.00 is trading 1.2% above its estimated GF Value™ of MXN357.71.
GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.
Key valuation signals for MEX:ACAD:
Forward Dividend Yield %: 0.00%
GF Value™: MXN357.71 vs. price of MXN362.00 (1.2% above fair value)
No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
73GF Score
Get the complete analysis for MEX:ACAD
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ACAD has been successfully added to your 